Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map® in Europe

OSLO, NORWAY – 7 November 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) today announces that GA has entered into an agreement with a leading non-disclosed global diagnostic company for the distribution of the GA-map® Dysbiosis Test in Europe.

GA and the diagnostic partner are now in the launch phase for selected European markets and expect this to fuel revenues from 2023.

There is increasing demand for gut microbiome assessments in the private healthcare service, medical clinics, and academic research globally. The GA-map® product offering will target labs performing services to both clinical diagnostic customers and clinical research customers. The GA-map® platform offers a fast turnaround lab testing service for microbiome analysis with an integrated software algorithm for immediate result presentation.

Ronny Hermansen, CEO, Genetic Analysis, comments:
“GA is thrilled to have signed up with this important partner for the European market and we are convinced that the GA-map® will be a significant add-on to their already strong product portfolio”.

For further information, please contact:
Ronny Hermansen, CEO

Eilert Aamodt, Chief Financial Officer

Please read the full press release in English:

Please also read the press release in Swedish language: